Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Tedeschi, A
Montillo, M
Miqueleiz, S
Draisci, M
Ricci, F
Scarpati, B
Mura, ME
Crugnola, M
Morra, E
机构：
[1] Univ Parma, Hematol & Transplant Unit, I-43100 Parma, Italy
[2] Osped Niguarda Ca Granda, Dept Pathol, Milan, Italy
[3] Osped Niguarda Ca Granda, Lab Transplant Immunol, Milan, Italy
[4] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5036
引用
收藏
页码：341B / 341B
页数：1
相关论文
共 50 条
  • [21] Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael
    O'Brien, Susan
    Kadia, Tapan
    Ferrajoli, Alessandra
    Faderl, Stefan
    Koller, Charles
    Garcia-Manero, Guillermo
    Burger, Jan A.
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 1332 - 1333
  • [22] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [23] Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL).
    Bosch, F
    Perales, M
    Cobo, F
    Esteve, J
    Rafel, M
    LopezGuillermo, A
    Ribera, JM
    Campo, E
    Montserrat, E
    BLOOD, 1997, 90 (10) : 2360 - 2360
  • [24] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL
    Wierda, W
    Faderl, S
    O'Brien, S
    Cortes, J
    Ferrajoli, A
    Giles, F
    Andreff, M
    Koller, C
    Kantarjian, H
    Keating, M
    BLOOD, 2004, 104 (11) : 101A - 101A
  • [25] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    HAEMATOLOGICA, 2014, 99 : 589 - 589
  • [26] Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Ferrajoli, Alessandra
    Badoux, Xavier C.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lee, Bang-Ning
    Reuben, James M.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2009, 114 (22) : 89 - 90
  • [27] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
    Grifi, Fatiha
    Bougherira, Soraya
    Djenouni, Amel
    LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
  • [28] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Montillo, Marco
    Tedeschi, Alessandra
    Petrizzi, Valeria Belsito
    Ricci, Francesca
    Crugnola, Monica
    Spriano, Mauro
    Spedini, Pierangelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    Vismara, Eleonora
    De Blasio, Angelo
    Zaccaria, Alfonso
    Morra, Enrica
    BLOOD, 2011, 118 (15) : 4079 - 4085
  • [29] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [30] Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada
    Isogai, Pierre K.
    Cheung, Matthew
    Mittmann, Nicole
    BLOOD, 2008, 112 (11) : 827 - 827
12345